Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
Sorana Segal‐Maurer(Gilead Sciences (United States)), Jean‐Michel Molina(Assistance Publique – Hôpitaux de Paris), Gary Sinclair(Proteogenomics Research Institute for Systems Medicine), Gary Richmond(University of Fort Lauderdale), Krittaecho Siripassorn(Bamrasnaradura Infectious Diseases Institute), Mezgebe Berhe, Antonella Castagna(Vita-Salute San Raffaele University), Nicolas Margot(Gilead Sciences (United States)), Jared M. Baeten(University of Washington), Peter Ruane, Edwin DeJesus(Orlando Immunology Center), Diana M. Brainard(Gilead Sciences (United States)), Martin S. Rhee(Gilead Sciences (United States)), Robert H. Hyland(Gilead Sciences (United States)), Hui Wang(Peking University), Hans‐Jürgen Stellbrink, Hadas Dvory‐Sobol(Gilead Sciences (United States))
Cited by 312
Related Papers
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k